| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 0.35 | 98.2% | 98.8% |
| Total Income | 0.35 | 98.2% | 98.8% |
| Expenditure | 55.49 | 1.3% | 2.5% |
| PBT | -72.01 | 314.8% | 332.5% |
| Net Profit | -72.01 | 314.8% | 332.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.61 | 306.7% | 238.9% |
NewAmsterdam Pharma Reports Q3 2025 Results; Cash Position at $756.0 Million
04 May 2026 · 4 May, 7:58 am
Summary
NewAmsterdam Pharma announced its financial results for the quarter ended September 30, 2025. The company reported a cash position of $756.0 million as of September 30, 2025. Revenue for the quarter was $0.3 million, a decrease from $29.1 million in the same period in 2024, primarily due to the recognition of revenue from a license agreement with Menarini in the previous year. The net loss for the quarter was $72.0 million, compared to a net loss of $16.6 million for the same period in 2024.
Key Highlights
- 1
NewAmsterdam Pharma had $756.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
- 2
Revenue for the quarter ended September 30, 2025, was $0.3 million, compared to $29.1 million for the same period in 2024.
- 3
Research and Development expenses were $31.0 million for the quarter ended September 30, 2025, compared to $35.7 million for the same period in 2024.
- 4
Selling, General and Administrative expenses were $24.5 million for the quarter ended September 30, 2025, compared to $18.4 million for the same period in 2024.
- 5
Net loss for the quarter ended September 30, 2025, was $72.0 million, compared to a net loss of $16.6 million for the same period in 2024.
- 6
The European Medicines Agency accepted for review the Marketing Authorization Applications for obicetrapib 10 mg monotherapy and the FDC of 10 mg obicetrapib plus 10 mg ezetimibe.
Management Comments
Michael Davidson
M.D.
"We remain acutely focused on our mission to deliver obicetrapib, as a novel, well-tolerated, and conveniently administered therapy for millions of patients with cardiometabolic disease who continue to struggle to reach their LDL-C goals." "In parallel, we continue to advance our broader clinical development strategy, including PREVAIL, our ongoing cardiovascular outcomes trial (“CVOT”), and REMBRANDT, our Phase 3 imaging trial. We are also making meaningful progress building our global infrastructure to support the potential launch of obicetrapib, if approved. As we engage with the investment and medical communities through upcoming conference and medical meetings, we look forward to sharing new pooled efficacy and safety data and to further highlighting our strategic vision for obicetrapib as a differentiated therapy in a large and growing market."
Informational and educational content only. Not investment advice.